Applied Therapeutics, Inc. (APLT)

Market Cap	15.70M -78.2%
Revenue (ttm)	1,000,000 -95.4%
Net Income	-18.14M
EPS	-0.13
Shares Out	152.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,704,732
Open	0.1036
Previous Close	n/a
Day's Range	0.1005 - 0.1100
52-Week Range	0.0900 - 1.5000
Beta	2.09
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2025

About APLT

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company’s lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-C...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2019
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: APLT
• Website: https://www.appliedtherapeutics.com

Financial Performance

In 2024, Applied Therapeutics's revenue was $455,000, a decrease of -95.45% compared to the previous year's $9.99 million. Losses were -$105.62 million, -11.81% less than in 2023.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error